Investor Relations by Aurelius Data

We are

Actionable Intelligence

Aurelius Data is the first global big data company using Deep Learning to analyze, predict, and find new cures, market trends, and IP in the cannabis and psilocybin markets.

Deep Analysis

Our Data Ecosystem combines patient use and satisfaction responses to create data points which are coupled with the full chemical compound analysis of the administered product.

Solid Data

Through use data, market intelligence, and analysis for manufacturers, dispensaries, and cultivators, we'll advance the research of pharmaceutical, healthcare, and food industries.

Why Aurelius Data

The founding team has deep pharmaceutical, biological and chemical knowledge, and the ability to quickly scale up ultra-high functional technical and field teams. We have deep connection into the market, engineering and scientific assets in place and the ability to execute mobile, web, and backend systems as well as cutting edge data science design and deployment.

We fill the gaps for usage, education, dosage, indication and application that providers and doctors are desperately needing. We significantly mitigate risk for the entire supply chain. The market wants and will pay for all data, negative and positive data. And patients are owed the truth.

Because clarity.

We are a patient use and perception focused deep learning company. By revealing the negative, and sometimes dangerous side effects, we mitigate risk. We create trust for patients and reveal the formulas that treat conditions reliably, with less harm and fewer side effects.

We go beyond the strain and flip the current data gathering systems upside down. We start with the patient and ask them to anonymously share their current pharmaceutical profile, their cannabis product use, their symptoms and medical conditions.

From this information, we can build large datasets and intuitive insights that determine which cannabinoid compounds create effective symptom relief. We also observe the negative side effects that cannabis compounds create in conjunction with traditional pharmaceuticals.

Because technology.

Our AI platform will have a baseline of over 4,000 real patient medical cases and can easily determine therapeutic outliers. From the raw anonymous data that we are constantly gathering via the app, web, and data partnerships, we will discover significant patient treatment patterns, and reveal the compounds responsible.

The mobile Aura platform feeds information into the data ecosystem through proprietary natural voice inputs, biometric analysis, optical scans of products, dynamic opt-in multi-platform social data, and organic engagement. The interaction of users with the education modules, the community closed forum, and the side effect search function, yields further correlative inputs.

Our subscription ecosystem-as-a-service, is a bi-directional software platform that bridges the mobile patient/consumer engagement application (AURA) with B2B and B2C transaction data, public data, and partner data.

Because partners.

Our advisory board is world class, industry savvy, and plugged into the data and tech industries. In addition, we have an entrée into the regulatory and legal environments and the ability to influence policy through our advisory board.

We have large pools of users through official data sharing partnerships with cannabis advocacy organizations (Americans for Safe Access), medical MSOs (Medical Marijuana Doctors), syndicated data companies (CRAC-Consumer Research Around Cannabis), POS Operators (Surfside), dispensaries, market research firms, manufacturers (Vuber), and cultivators.

Because scalability.

The platform in development can be scaled into other areas and products that require medical observational research and data such as BigPharma, Doctors, Patients, Clinicians, Retailers, Food and Beverage/CPG industry, Pet RX Industry, Healthcare organizations, political lobbyists. Revenue will also come from 3 other streams; Large dataset sales, White labeling of tailored instances of AURA , and Licensing and sales of IP. (Example of IP is discovery of a new patentable compound combination that creates symptom resolution for restless legs syndrome or post-partum depression, or revelation of new beneficial side effects from common strains.)

Need more information?

If you are interested in partnering and want to take a deeper dive, please submit your name and email to request access to more detailed information about us.

We are

Actionable Intelligence

Deep Analysis

Solid Data

Why Aurelius Data

Need more information?

Our partnerships

you're almost there . . .

We just need some contact info.

Enter your email below to get access to our deck, learn about us, and start a journey together to go beyond the strain to help us build patient trust .

you're almost there . . .

We just need some contact info.

Enter your information below to get access to our deck, learn about us, and start a journey together to go beyond the strain to help us build patient trust .